Market capitalization | $83.94m |
Enterprise Value | $59.54m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.02 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-39.07m |
Free Cash Flow (TTM) Free Cash Flow | $-29.77m |
Cash position | $34.36m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
8 Analysts have issued a Achieve Life Sciences, Inc. forecast:
8 Analysts have issued a Achieve Life Sciences, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.23 -0.23 |
28%
28%
|
|
EBITDA | -39 -39 |
44%
44%
|
EBIT (Operating Income) EBIT | -39 -39 |
43%
43%
|
Net Profit | -40 -40 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Head office | United States |
CEO | Richard Stewart |
Employees | 25 |
Founded | 1991 |
Website | www.achievelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.